That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

The third-quarter results encouraged Pfizer to bump up its annual revenue expectations for Comirnaty and Paxlovid to $10.5 billion, from its previous forecast of $8.5 billion.

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Pfizer rides Paxlovid sales growth to better-than-expected third quarter FILE - The Pfizer logo is displayed at the company’s headquarters, Friday, Feb. 5, 2021, in New York.

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

Pfizer said in a statement that 93% of health insurers cover Paxlovid. Yet some policyholders may face pricey copays.

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a U.S. national stockpile delivery led to $2.7 billion in sales for the drug, Pfizer said Tuesday.

A Pfizer spokesperson said in a statement that the company remains confident in Paxlovid’s clinical effectiveness at preventing hospitalizations and deaths in patients at high risk of severe ...

When Laura Martin tested positive for COVID-19 last month during an extended stay in California, she was prescribed Paxlovid, the highly touted antiviral drug created by Pfizer. Just one day after ...